IGF-1 LR3 vs IGF-1 DES: How Two Growth-Factor Analogs Differ

Native IGF-1 is a 70-amino-acid growth factor. IGF-1 LR3 adds an N-terminal extension and an arginine substitution; IGF-1 DES removes the first three residues. Both modifications reduce interaction with IGF-binding proteins, but they are different molecules with different masses, and published findings for one cannot be transferred to the other.

Native IGF-1: the parent molecule

Insulin-like growth factor 1 is a 70-amino-acid single-chain protein with a molecular mass near 7.6 kDa. It signals mainly through the IGF-1 receptor and is regulated in circulation by a family of IGF-binding proteins (IGFBPs) that control how much free IGF-1 reaches a receptor.

Those binding proteins are the key to understanding the modified analogs. Most IGF-1 analog research asks one question: what happens to receptor signaling when binding-protein interaction is reduced?

IGF-1 LR3: extension plus substitution

IGF-1 LR3 (long arginine 3 IGF-I) is an 83-amino-acid analog. It adds a 13-residue extension peptide at the N-terminus and substitutes arginine for glutamic acid at position 3. Both changes lower its affinity for IGF-binding proteins, so a larger fraction remains available to the receptor in experimental systems.

Tomas and colleagues infused long-R3 IGF-I in guinea pigs and reported organ-growth effects alongside reduced plasma IGF-I, IGF-II and IGF-binding-protein concentrations. That study characterizes the named experimental material in one animal model; it does not define a universal half-life or potency multiplier for every vial sold under the LR3 name.

IGF-1 DES: the truncated analog

IGF-1 DES, or Des(1-3) IGF-I, removes the first three amino acids (Gly-Pro-Glu) of mature IGF-1, leaving a 67-residue chain. The truncation also reduces binding-protein affinity, but through a different structural change than LR3 — so DES and LR3 are not interchangeable constructs.

Ballard and colleagues reviewed the biochemical and biological properties of Des(1-3) IGF-I, and a later comparative study in pigs and marmoset monkeys found that IGF analogs binding poorly to binding proteins showed more potent and prolonged hypoglycaemic action than native IGF-I. These are construct-specific findings in defined models, not evidence about any particular catalog vial.

Side by side: what actually differs

Structure: native IGF-1 has 70 residues; LR3 has 83 with an Arg3 substitution; DES has 67. Their theoretical masses differ accordingly, which is exactly what LC-MS identity testing exploits.

Binding proteins: both analogs interact less with IGFBPs than native IGF-1, but the magnitude and consequences depend on the model, the binding protein and the assay. Neither analog's behaviour can be predicted from the other's data.

Evidence: LR3 and DES each have their own published literature, largely animal and biochemical work. Neither has an established human therapeutic evidence base, and findings for native IGF-1 do not automatically apply to either analog.

Where IGF-2 LR3 fits

IGF-2 LR3 applies the same design idea to insulin-like growth factor 2: a long-R3-style modification of the IGF-2 sequence rather than IGF-1. It is a different parent molecule, so IGF-1 LR3 findings cannot be transferred to it.

Published construct-specific data for IGF-2 LR3 are scarce, and the exact construct sold under that name has not been confirmed against an original specification and matching lot evidence. Until that documentation exists, its identity and any performance claims remain unverified.

How to Verify Peptide Authenticity

What remains unverified

Frequently repeated figures — a fixed potency multiplier, a precise half-life, or localized-versus-systemic action claims — vary by study design and are not established constants. This article does not present them as facts for any specific inventory.

Identity is also separate from evidence. A vial labelled IGF-1 LR3 or IGF-1 DES should be confirmed against an original construct specification and a matching lot's observed intact mass before any published finding is considered relevant to it.

Peptide Purity vs Identity vs Content

How to verify which construct you have

Start with the specification: full sequence, modifications, formula and theoretical mass. For LR3 that means the 83-residue long-R3 sequence; for DES, the 67-residue truncated sequence.

Then match the lot. LC-MS should show an observed intact mass consistent with the stated construct, and HPLC purity and quantitative content are separate measurements reported alongside it. A label or product photo is not identity evidence.

How Peptide Lab Verification Works

Evidence guides

How Peptide Lab Verification Works — How HPLC, LC-MS, content testing and lot records fit together.
How to Verify Peptide Authenticity — A checklist for identity, lot matching and report provenance.
How to Choose a Research Peptide Supplier — Evaluate suppliers on specifications, documentation and handling.
Peptide Purity vs Identity vs Content — Why purity, identity and net peptide content are separate measurements.

Frequently asked questions

Is IGF-1 LR3 the same as IGF-1 DES?

No. LR3 is an 83-amino-acid analog with an N-terminal extension and an arginine substitution at position 3; DES is a 67-residue analog missing the first three amino acids. They differ in structure, mass and published evidence.

Why were these analogs made?

Both modifications reduce interaction with IGF-binding proteins, which lets researchers study IGF-receptor signaling when more of the analog remains freely available in an experimental system.

Does reduced binding-protein affinity prove greater potency?

Not as a fixed number. Comparative animal studies found more potent and prolonged effects for poorly binding analogs in specific models, but the magnitude depends on the model and assay and cannot be stated as a universal multiplier.

Can IGF-1 research findings be applied to humans?

The cited work is animal and biochemical research. It establishes research questions, not human effectiveness or safety, and these materials are sold strictly for research use.

How do I confirm a vial contains the stated analog?

Obtain the construct specification with its theoretical mass, then compare a matching lot's LC-MS intact-mass result against it. Purity and quantity are separate measurements.

References

More peptide science

Research Use Only. Educational laboratory information; not medical advice.